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The time necessary for a treatment to become effective is crucial for patients and physicians but has been largely
neglected in the reporting and comparison of clinical trials in dermatology. The aim of this systematic review is to
determine the time until the onset of action (TOA) of systemic agents approved for moderate-to-severe psoriasis.
Primary outcome is the TOA defined as the weighted mean time until 25% of the patients achieved a psoriasis
area and severity index (PASI) 75 response. Among the biologics, infliximab has the shortest TOA (3.5 weeks),
followed by ustekinumab (high dose 4.6/low dose 5.1 weeks/not weight adapted), adalimumab (4.6 weeks),
etanercept (high dose 6.6/low dose 9.5 weeks), and alefacept (high dose 15.4 weeks/low dose: no data). Among
the conventional treatments, good data are available for cyclosporine A (CsA; TOA: 6.0 weeks) and limited data
are found for methotrexate (MTX; TOA: high dose 3.2/low dose 9.9 weeks). No data are available for fumaric acid
esters and retinoids. This systematic review provides clinically relevant information on the onset of action of
antipsoriatic agents, although the data currently available allow only a limited assessment. Psoriasis trials should
consider including TOA as an additional outcome measure.
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INTRODUCTION
Different treatment options are available for the treatment of
psoriasis, including topical treatments, UV therapy, and sys-
temic treatments. For moderate or severe disease, UV treat-
ment or systemic treatment is usually recommended (Smith
et al., 2005; Pathirana et al., 2009; Nast et al., 2011). Many
different aspects have to be considered when choosing an
appropriate antipsoriatic treatment for a patient. The current
guidelines suggest taking efficacy, safety, practicability for
physicians and patients, as well as costs into consideration
(Burden et al., 2010; Nast et al., 2011). However, the time
necessary for a patient to achieve a significant improvement in
the skin disease has been an aspect largely neglected in
existing reviews and guidelines. Discreet choice experiments
have shown that the time necessary to achieve moderate
improvements is of large importance to the patients and it is
favored over aspects such as time until relapse (Seston et al.,
2007). Very acute and severe forms of psoriasis will require a
treatment with a very rapid onset of action, whereas patients
with a long-standing history of psoriasis with a stable disease
may be more willing to accept a slow onset of action if the
treatment offers other advantages or a better safety profile.
In clinical trials on psoriasis, the Psoriasis Area and Severity
Index (PASI) is usually used to measure disease severity. The
PASI 75 response, which means the percentage of patients
achieving at least a PASI reduction of 75%, serves as an
efficacy parameter in psoriasis treatment guidelines (Pathirana
et al., 2009). Another parameter addressing changes in the
PASI is the mean reduction in the PASI of all patients in the
trial. A reduction in the PASI by 50% or by 75% in individual
patients have been suggested and discussed as clinical
meaningful outcomes (Krueger et al., 2000; Carlin et al.,
2004; Katz, 2005; Schafer et al., 2010; Mrowietz et al., 2011).
Estimates on how long a treatment requires to become
effective can be given based on data on the course of the
mean PASI or derived from the curve of the percentage of the
patients achieving at least a PASI 75 response after a certain
time. We aim to determine the time needed for specific
antipsoriatic drugs to achieve a given treatment goal.
RESULTS
After systematic literature search and screening for eligibility,
49 studies with 66 relevant study arms on biologics (adalimu-
mab, alefacept, etanercept, infliximab, and ustekinumab) and
nonbiologic systemic monotherapies (cyclosporine A (CsA),
fumaric acid esters, methotrexate (MTX), and retinoids) were
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included in this review (Figure 1). Alefacept, CsA, etanercept,
MTX, and ustekinumab were investigated in different dosages,
which were not dependent on body weight.
Characteristics of the included study arms
Of the 49 included studies, 44 were placebo controlled,
verum controlled, or both placebo and verum controlled,
and the remaining 5 studies were uncontrolled. As measured
by the Cochrane Risk of Bias Tool, the quality of studies within
each drug group ranged mainly from low to high (data
available on request). Because of the low number of trials,
sensitivity analysis could not be performed to evaluate bias
rising from trials with different methodological quality.
The reported mean baseline PASI ranged from 13 to 32 in
the study populations. Minimal washout periods of 2 weeks
for low-to-moderate-potency topical steroids and of 4 weeks
for systemic therapies, high-potency topical steroids, or
UVB/psoralen plus UVA were stated in most of the studies.
A 1-week washout period for topical treatment was reported
in four study arms and a 2-week washout period for any
treatment was reported in four study arms. Any information
regarding washout periods was not given in almost half of the
study arms. Concurrent topical treatment (emollients, low-to-
mid-potency corticosteroids) was allowed in 16 of 38 study
arms investigating biologics, in 2 of 3 study arms with fumaric
acid esters, in 3 of 9 MTX study arms, and in 2 of 13 study
arms evaluating CsA. Topical treatment was not permitted in
four study arms with biologics, in three investigating MTX, in
both with retinoids, and in seven study arms of CsA. No
information on concurrent topical treatment was provided for
27 of all evaluated study arms. Detailed information on
characteristics of the included study arms is available as
Supplementary Table S1 online.
Primary outcomes: time until 25% of patients achieve PASI 75
In all, 34 study arms provided data on the time necessary for
25% of the patients to achieve a reduction in PASI of at least
75%. In the studies with adalimumab (3 study arms, n¼933),
time until 25% of patients achieved a PASI 75 response was
4.6 weeks (Menter et al., 2008; Revicki et al., 2008; Saurat
et al., 2008; Noda et al., 2012). This outcome was reached
with high-dose alefacept within 15.4 weeks (1 study arm,
n¼49) (Lui et al., 2012). During treatment with low-dose
etanercept (2 25 mg or 150 mg per week), a duration of
9.5 weeks was necessary to achieve a PASI 75 response in
25% of the patients (2 study arms, n¼ 153) (Gottlieb et al.,
2003; van de Kerkhof et al., 2008). On using a dosage of
250 mg of etanercept (5 study arms, n¼1.177) a period of
6.6 weeks was required to reach this outcome (Tyring et al.,
2007; Griffiths et al., 2010; Gottlieb et al., 2011, 2012; Strober
et al., 2011). A treatment with infliximab (7 study arms,
n¼1.710) showed PASI 75 response in 25% of patients within
3.5 weeks (Reich et al., 2005; Menter et al., 2007; Torii and
Nakagawa, 2010; Barker et al., 2011; Noda et al., 2012;
Yang et al., 2012). On using a slow-increase dosage schedule
for MTX (3 study arms, n¼ 488), a duration of 9.9 weeks was
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Figure 1. Flow of information through the different phases of literature evaluation.
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necessary (Revicki et al., 2008; Saurat et al., 2008; Barker
et al., 2011; Reich et al., 2011). During treatment with MTX
with an initial dosage of 7.5 mg and an immediate increase to
15 mg in the second week, the patients showed a very quick
onset of action within 3.2 weeks (1 study arm, n¼ 18)
(Akhyani et al., 2010). On using low-dose ustekinumab (five
study arms, n¼998) a period of 5.1 weeks was required
(Leonardi et al., 2008; Papp et al., 2008; Griffiths et al., 2010;
Tsai et al., 2011; Igarashi et al., 2012) and with high-dose
ustekinumab a period of 4.6 weeks was required (4 study
arms, n¼ 1.076) (Leonardi et al., 2008; Papp et al., 2008;
Griffiths et al., 2010; Igarashi et al., 2012). Patients treated
with low-dose CsA showed an onset of action within 6.0
weeks (3 study arms, n¼339) (Koo, 1998; Vena et al., 2012).
No suitable data for this outcome were available for low-dose
alefacept, fumaric acid esters, and retinoids. Individual study
results can be seen in Figure 2 and in the Supplementary
Table S2 online.
Secondary outcomes: time necessary for 25% reduction in the
mean initial PASI and time necessary for 50% reduction in the
mean initial PASI
A total of 38 study arms provided data on the mean PASI
reduction. Of these, 36 study arms were suitable for data
extraction with respect to the time necessary for a mean PASI
reduction by 25% and 35 study arms were suitable with
respect to the time necessary for a mean PASI reduction
by 50%. Results of this secondary outcome are shown in
Figures 3 and 4. Detailed information on individual study
results are presented in Supplementary Table S2 online.
In patients treated with adalimumab (1 study arm, n¼108),
time periods of 1.6 and 3.5 weeks were necessary to lower the
mean PASI by 25% and 50%, respectively (Revicki et al.,
2008; Saurat et al., 2008). On treating patients with low-dose
alefacept (two study arms, n¼ 367), a mean PASI reduction by
25% was achieved within a period of 8.0 weeks (Krueger
et al., 2002). No suitable data were found for low-dose
alefacept with respect to a 50% mean PASI reduction.
Treatment with high-dose alefacept needed a period of
6.7 weeks to reduce the mean PASI by 25% (1 study arm,
n¼46) (Huang et al., 2008). In this study, a mean PASI
reduction by 50% was not achieved within the whole study
period of 24 weeks and no assumption could be made on how
much longer it would have taken to reach this result. That is
why the weighted mean PASI reduction by 50% was not
calculated for high-dose alefacept, although two other study
arms provided 50% mean PASI reduction data (Gribetz et al.,
2005). During treatment with low-dose CsA, a period of
2.3 weeks was required for a 25% reduction and a period of
5.4 weeks was required for a 50% reduction in the mean PASI
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Figure 2. Time until 25% of patients achieve a PASI 75 response: distribution
of the individual study results. CsA, cyclosporine A; MTX, methotrexate; PASI,
psoriasis area and severity index.
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Figure 3. Time necessary for 25% reduction in the mean initial PASI:
distribution of the individual study results. CsA, cyclosporine A; MTX,
methotrexate; PASI, psoriasis area and severity index.
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Figure 4. Time necessary for 50% reduction in the mean initial PASI:
distribution of the individual study results. CsA, cyclosporine A; MTX,
methotrexate; PASI, psoriasis area and severity index.
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(8 study arms, n¼ 359) (Grossman et al., 1994; Elder et al.,
1995; Mahrle et al., 1995; Meffert et al., 1997; Heydendael
et al., 2003; Yoon and Youn, 2007; Vena et al., 2012). Patients
treated with high-dose CsA achieved a reduction in the mean
PASI by 25% within a period of 1.6 weeks and a reduction in
the mean PASI by 50% within a period of 3.1 weeks (4 study
arms, n¼ 211) (Finzi et al., 1993; Laburte et al., 1994;
Reitamo et al., 2001; Yoon and Youn, 2007). Patients
treated with low-dose etanercept (3 study arms, n¼811)
required time periods of 3.5 and 10.9 weeks to lower the
mean PASI by 25% and 50%, respectively (Leonardi et al.,
2003; Costanzo et al., 2005; van de Kerkhof et al., 2008).
With high-dose etanercept, a period of 2.9 weeks was
necessary for a 25% reduction and a period of 6.5 weeks
was required for a 50% reduction in the mean PASI (2 study
arms, n¼226) (Leonardi et al., 2003; Bagel et al., 2012).
Fumaric acid esters (3 study arms, n¼ 250) required a period
of 3.7 weeks for a 25% reduction and a period of 8.1 weeks
for a 50% reduction in the mean PASI (Altmeyer et al., 1996;
Mrowietz et al., 1998; Gollnick et al., 2002). On treating
patients with infliximab (2 study arms, n¼ 21), a period of
1.5 weeks was necessary to achieve a PASI reduction by 25%
and a period of 3.7 weeks was necessary to lower the PASI by
50% (Chaudhari et al., 2001; Lemme et al., 2007). Low-dose
MTX (5 study arms, n¼ 329) required time periods of 4.0 and
10.0 weeks for a PASI reduction by 25% and 50%, respectively
(Chladek et al., 2008; Hroch et al., 2008; Revicki et al., 2008;
Saurat et al., 2008; Reich et al., 2011; Dogra et al., 2012).
During treatment with high-dose MTX (3 study arms, n¼ 92),
a 25% reduction in the mean PASI was achieved within a
period of 1.9 weeks and a 50% reduction was achieved within
a period of 3.9 weeks (Heydendael et al., 2003; Akhyani et al.,
2010; Dogra et al., 2012). With retinoids (acitretin), a period
of 2.9 weeks was required to reduce the mean PASI by 25%
reduction and a period of 6.5 weeks was required for a
reduction in the mean PASI by 50% (2 study arms, n¼ 79)
(van de Kerkhof et al., 1998; Caca-Biljanovska and V’Lckova-
Laskoska, 2002). No suitable data were found for ustekinumab
with respect to secondary outcomes.
DISCUSSION
A good knowledge of the time necessary until an antipsoriatic
treatment becomes effective is important to select a treatment
that corresponds to the patients’ needs and expectations.
The rapidity of the onset of a treatment has rarely been
taken into consideration as a specific outcome in the clinical
trials. Current guidelines do not consider time until the
onset of action (TOA) as a criterion for drug selection
(Smith et al., 2005; Pathirana et al., 2009; Burden et al.,
2010; Scottish Intercollegiate Guidelines Network (SIGN),
2010; Nast et al., 2011).
Our review provides a summarized comparison of TOA
between different treatments for psoriasis. For adalimumab,
etanercept, infliximab, CsA, low-dose MTX, and ustekinumab,
at least two study groups were available for the outcome
‘‘25% of the patients achieving a PASI 75 response.’’ Among
biologics, infliximab needs the shortest time until a PASI 75
response is reached by 25% of the patients, followed by
ustekinumab, adalimumab, etanercept, and alefacept. The
results correspond well with our experiences from clinical
practice. For etanercept and ustekinumab, the primary out-
come could be analyzed for low and high dosages. The
expected faster response on the high dosage occurs only with
etanercept. The TOA results of low-dose ustekinumab
do not differ from the results from study arms investigating
high dosage, although the dosage in the studies was not
dependent on the body weight, and the distribution of weight
between the study groups was similar. As both TOA values
were quite fast (by B5 weeks), a saturation may be reached
where a dosage increase had no influence on the result
anymore.
Among nonbiologics, CsA in a low dosage needs more time
compared with high-dose MTX but less time compared with
low-dose MTX to reach the PASI 75 response in 25% of the
patients. The very fast onset seen with a dosage of 15 mg per
week MTX after 3.2 weeks is surprising. This result, which is
based on one study only, is likely to be biased because of the
very small sample size (n¼ 18) (Akhyani et al., 2010).
However, when looking at the subgroup analysis of early
responders as done for the Champion trial by Saurat et al.
(2011), the subgroup of responders also showed a rather fast
onset of action after increasing the dose, leading to a mean
PASI reduction of 21.2% within a time period of 2 weeks. In a
subgroup of patients who respond well to MTX, the onset of
action may therefore be seen rather fast. More data are
necessary to draw reliable conclusions on the onset of
action of high-dose MTX. As expected, TOA for low-dose
MTX is longer compared with that for high-dose MTX and
corresponds well with the onset of action seen in our clinical
practice. Results of low-dose CsA are based on more reliable
data compared with high-dose MTX and show that CsA is
faster than etanercept but needs more time to act compared
with infliximab, adalimumab, or ustekinumab.
For the secondary outcome, the mean PASI reduction in all
patients, more data were available. Again, infliximab, adali-
mumab, and ustekinumab show very fast onsets of action. CsA
data on the time necessary for 25 or 50% reduction in the
mean PASI support the primary outcome that patients treated
with CsA also experience a fast improvement in symptoms.
The possibly fast onset of action of high-dose MTX seen in the
data generated for the primary outcome is corroborated
in this analysis by a second trial. As seen in the primary
outcome analysis, etanercept, fumaric acid esters, low-dose
MTX, and alefacept required more time to act when compared
with infliximab, adalimumab, and CsA for the secondary
outcomes.
The data available to perform such a comparison are limited
and the taken approach provides a general estimate on the
TOA of the different drugs. Important methodological limita-
tions apply. The review assumes a linear course of the PASI
response between the different measured time points. Most
PASI data were provided at time points in a 4-week interval,
limiting precision of the estimation of the TOA. If PASI data at
more frequent time points within the first weeks of treatment
had been provided, the generated results could have been
more precise. Another limitation associated with the approach
A Nast et al.
Time Until Onset of Antipsoriatic Drugs
1966 Journal of Investigative Dermatology (2013), Volume 133
of reading out the PASI response and corresponding time data
from the graphs is that measures of variation (e.g., SD) were
not available and confidence intervals of the TOA outcome
could not be calculated.
To a certain extent, this analysis is influenced by the overall
response rate of a drug. This applies especially to the mean
PASI reduction, because the nonresponders do delay the
measurable response of the responders. For this reason, the
time until 25% of patients reach a PASI 75 response was
chosen as the primary outcome, as the nonresponder popula-
tion does not influence this part of the outcome curve. The
PASI 75 response is accepted as a clinically relevant improve-
ment and considered as an efficacy parameter in psoriasis
guidelines. Our primary outcome might not be assumed as a
meaningful parameter if only a quarter of patients achieve the
75% reduction in the initial PASI. The time until PASI 75
response or PASI 50 response is achieved in 50% of patients
might be a more relevant indicator. However, the outcome
selection was done with respect to the availability and
comparability of the data in the trials, especially as with
some drugs a PASI 75 response is not even achieved by 50%
of the patients. The secondary outcomes, time until 25 or
50% reduction in the mean PASI, relate to clinical relevant
targets, but look at the responders and nonresponders
together. The 25% reduction is less affected by nonresponders
than the 50% reduction, and can therefore be considered the
more reliable secondary outcome. A low efficacy in many
patients would be more visible in the mean PASI reduction
results, whereas a small group of fast responders with many
nonresponders would become more evident in the 25% PASI
75 response group.
A possible bias due to heterogeneity of the studies on the
calculated TOA data cannot be excluded. Homogeneity of the
trials has been tried to be assured by a comparison of the
initial PASI, washout phases, and concurrent topical treat-
ments that might influence the study outcomes. A very high
initial PASI may allow for a more significant and faster
reduction in the first weeks. Recently, attention has been
turned to the so-called ‘‘eligibility creep,’’ describing a
tendency of patients to have higher measured severity at
initial assessment visits when eligibility is determined and
inclusion criteria have to be met (Hick and Feldman, 2007).
This influences overall efficacy of the drug and also the
rapidity of the onset of action. In the included study arms,
patients suffered from moderate-to-severe psoriasis with
differences between trials of B20 points in the initial PASI.
Looking at the same antipsoriatic drugs, TOA results of
individual studies with initial PASI X25 obviously do not
differ from data of studies with initial PASI o25. However,
because of the low number of trials for the different drugs,
sensitivity analysis could not be performed and the possibility
of a bias derived from this aspect has to be considered when
interpreting the results.
Small differences between the studies were found in the use
of concurrent topical treatment. Although in some trials any
concurrent topical treatment was prohibited, several studies
allowed applying emollients or corticosteroids with low to
mild potency. We still considered the influence of low and
moderate topical steroids on the TOA as marginal. Unfortu-
nately, a lack of information for some trials does not allow
evaluating the impact of any potent concomitant medication
in the related study arms.
Reported washout phases of 2 to 4 weeks for topical and of
4 to 12 weeks for systemic therapies were quite similar. Four
studies (Elder et al., 1995; Mrowietz et al., 1998; van de
Kerkhof et al., 1998; Dogra et al., 2012) differ from this
approach with shorter washout periods, but it does not seem
to affect the outcome as the TOA results of these studies were
in the range of other studies investigating the drugs. Because of
missing information in a large proportion of the included
studies, potential influence of different washout phases on the
results cannot be excluded.
By grouping of drugs in low and high dosages, the
comparability of the study interventions should be improved.
Looking at the primary and secondary outcomes, the effect of
an increased dosage can be seen for all drugs by a faster TOA,
with the exception of ustekinumab as mentioned before.
Grouping of alefacept, CsA, etanercept, and ustekinumab
follows the standard dosage regime recommended by the
manufacturers, but low and high doses of MTX were defined
by authors on the basis of clinical experience and can be a
source of bias. However, the manufacturer’s recommendation
of MTX allows a high variability in dosage regime, which
could not be completely controlled by grouping. Grouping of
retinoid trials by dosage was not possible because of the small
number of studies. The dosage differences between the
retinoid studies resulted in less comparability, which can
cause some imprecision in the weighted mean of TOA.
Unfortunately, because of limited studies providing data for
the different outcomes, we were not able to perform a
sensitivity analysis and could not evaluate bias that arise from
different study quality. However, we tried to control bias
based on small trials by calculating a weighted mean, taking
into account the number of patients.
So far, the TOA has been neglected as an outcome criterion
in clinical trials. The right choice of a treatment that is suitable
to a patient’s need is a prerequisite for adherence. As the
scope of this review was to determine TOA in a first approach,
we do not provide data on general efficacy and safety of
systemic antipsoriatic drugs (Schmitt et al., 2008; Singh et al.,
2011). Existing reviews on safety and general efficacy
should be used in addition to this review to complete the
view on the discussed drugs. Taken together, time until
onset, final improvement, and adverse events of drugs are
highly relevant for therapeutic decisions and should
be considered when weighting benefit and harm. However,
for such a comprehensive analysis, more precise study data
are necessary to draw a valid conclusion.
In summary, our review gives information on time until
antipsoriatic drugs become effective. TOA should be con-
sidered as a part of the reporting of clinical trials in the
future to gain more valid data. If a drug with a slow onset of
action is chosen, the patient should be informed and should
agree with this, or a combination treatment should be chosen,
adding a fast therapy such as UV therapy or high-potency
corticosteroids.
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MATERIALS AND METHODS
We systemically reviewed original articles reporting on clinical trials
for licensed biologic and nonbiologic systemic monotherapies for
patients suffering from moderate-to-severe psoriasis vulgaris with
respect to available data for TOA.
Identification of articles
All relevant trials published until November 2009 were identified
using the results of the systematic search done by our group for the
German S3 psoriasis guidelines (Nast et al., 2011). As alefacept was
not part of the German guidelines, a complete de novo search for the
time period until December 2008 was performed, with the search
terms ‘‘psoriasis’’ and ‘‘alefacept.’’ We then updated both the
literature searches for the dates January 2009 to 13 July 2011. The
search was done using the terms ‘‘psoriasis’’ and ‘‘acitretin’’
or ‘‘adalimumab’’ or ‘‘alefacept’’ or ‘‘cyclosporine’’ or ‘‘etanercept’’
or ‘‘fumaric acid esters’’ or ‘‘infliximab’’ or ‘‘methotrexate’’ or
‘‘ustekinumab.’’ MeSH terms and title and abstracts were searched.
A second update of the literature search was done on 18 October
2012 using the same search strategy (see also Figure 1). All searches
were performed in Medline, Embase, and the Cochrane Library.
The selection criteria for relevant interventions for the treatment of
moderate-to-severe chronic plaque psoriasis were in accordance with
the German and European psoriasis guidelines (Nast et al., 2011;
Pathirana et al., 2009). Studies had to be clinical trials investigating at
least 10 adult patients in each treatment group with moderate-to-
severe psoriasis vulgaris and were treated with one of the included
systemic. The studies were included in this review if a baseline PASI
of at least eight was an inclusion criterion for patients or a PASI of
eight was the minimal reported initial value in the study population.
Relevant outcome data (mean PASI reduction or PASI 75 response)
had to be provided for at least three time points at least every 4 weeks
during the observed treatment period either in tables, texts, or graphs.
Primary outcome for this systematic review was the time necessary
for 25% of the patients in a trial population to achieve at least a PASI
75 response.
Secondary outcomes were the time necessary to achieve a reduc-
tion of 25% and 50% of the mean PASI in the included patient
populations.
Because of the lack of sufficient data in the included trials to allow
for a comparative analysis, other relevant outcomes such as PASI 90
or DLQI (Dermatology Life Quality Index) data were not further
analyzed after initial check for availability.
The abstracts were independently screened by two investigators
(DP and SR); differences were resolved by discussion.
Data extraction
Data extraction was done independently by two investigators
(SR and BS). Differences were resolved by discussion. Whenever
possible, PASI response and mean PASI reduction data were directly
extracted for the relevant time points from the tables or texts of the
included trials. In most cases, data were provided within graphs only.
In these cases, we used Engauge Digitizer Software (http://digitizer.
sourceforge.net/, accessed 5 September 2012) to read out these data
from the graphs. The Engauge Software allows to match a graph with
a given scale and to extract the displayed values. The software was
validated performing 25 read outs on six different studies where
data were provided in a graphic form as well as in tables or text
(Gollnick et al., 2002; Heydendael et al., 2003; Leonardi et al., 2003;
Tyring et al., 2007; Hroch et al., 2008; Leonardi et al., 2008; ). The
mean deviation of the Engauge-extracted data from data provided in
texts or tables is considered to be negligible (0.24% ( 0.16 to 0.64)).
Only study arms with licensed dosages were considered for these
analyses. For those drugs, where different dosages are licensed or
commonly used, study arms were grouped according to the applied
dosage in low and high doses: low-dose (7.5 mg) and high-dose
(15 mg) alefacept; low-dose (o5 mg/kg bodyweight) and high-dose
(X5 mg/kg bodyweight ) cyclosporine; low-dose (2 25 or 1 50 mg)
and high-dose (2 50 mg) etanercept; low-dose (o15 mg) and high-
dose (X15 mg) MTX; and low-dose (45 mg) and high-dose (90 mg)
ustekinumab. If dosage adjustments were performed during the course
of the treatment, the dosage that was used most of the time during the
time period in focus was used for the grouping.
Data analysis
A linear course of PASI response between the provided time points
(e.g., between baseline and week 4) was assumed as a model for this
analysis and the PASI data and their corresponding time value were
used to calculate the TOA for the drugs in each trial. Study arms on
the same drug and with comparable dosages providing the same
outcome criteria were grouped. After checking for sufficient compar-
ability, e.g., with respect to disease severity, the TOA data were
summarized for each drug. Summarizing was done by means of
calculating a weighted mean, taking into account the number of
patients in every study arm. Results are presented in table form and
displayed graphically.
The quality of the trials included was assessed using the Cochrane
Risk of Bias Tool (Higgins et al., 2011). We aimed to perform
sensitivity analysis to control bias arising from trials with different
methodological quality. This review was performed in accordance
with the requirement set forth by the PRISMA statement (Moher
et al., 2009).
CONFLICT OF INTEREST
AN has received honoraria for CME certified educational talks that received
indirect sponsoring from Abbott, Pfizer, and Jansen Cilag. AN, BS, SR, DP, AJ,
and RNW: the Division of Evidence-Based Medicine has received research
grants from Wyeth (now Pfizer) and Abbott. JS has received research grants
from Wyeth and from Novartis, honoraria for CME certified educational talks
that received indirect sponsoring from Abbott and Novartis, and has received
honoraria as an advisory board member from Novartis. The mentioned
pharmaceutical companies did not influence this work. The selection of the
primary and secondary outcomes as well as the performance of the analysis
was done independently from industrial interest.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper at http://
www.nature.com/jid
REFERENCES
Akhyani M, Chams-Davatchi C, Hemami MR et al. (2010) Efficacy and safety
of mycophenolate mofetil vs. methotrexate for the treatment of chronic
plaque psoriasis. J Eur Acad Dermatol Venereol 24:1447–51
Altmeyer P, Hartwig R, Matthes U (1996) Efficacy and safety profile of fumaric
acid esters in oral long-term therapy with severe treatment refractory
psoriasis vulgaris. A study of 83 patients. Hautarzt 47:190–6
Bagel J, Lynde C, Tyring S et al. (2012) Moderate to severe plaque psoriasis
with scalp involvement: a randomized, double-blind, placebo-controlled
study of etanercept. J Am Acad Dermatol 67:86–92
A Nast et al.
Time Until Onset of Antipsoriatic Drugs
1968 Journal of Investigative Dermatology (2013), Volume 133
Barker J, Hoffmann M, Wozel G et al. (2011) Efficacy and safety of infliximab
vs. methotrexate in patients with moderate-to-severe plaque psoriasis:
results of an open-label, active-controlled, randomized trial (RESTORE1).
Br J Dermatol 165:1109–17
Burden AD, Hilton Boon M, Leman J et al. (2010) Diagnosis and management
of psoriasis and psoriatic arthritis in adults: summary of SIGN guidance.
BMJ 341:c5623
Caca-Biljanovska NG, V’Lckova-Laskoska MT (2002) Management of guttate
and generalized psoriasis vulgaris: prospective randomized study. Croat
Med J 43:707–12
Carlin CS, Feldman SR, Krueger JG et al. (2004) A 50% reduction in the
Psoriasis Area and Severity Index (PASI 50) is a clinically significant
endpoint in the assessment of psoriasis. J Am Acad Dermatol 50:
859–66
Chaudhari U, Romano P, Mulcahy LD et al. (2001) Efficacy and safety of
infliximab monotherapy for plaque-type psoriasis: a randomised trial.
Lancet 357:1842–7
Chladek J, Simkova M, Vaneckova J et al. (2008) The effect of folic acid
supplementation on the pharmacokinetics and pharmacodynamics
of oral methotrexate during the remission-induction period of treatment
for moderate-to-severe plaque psoriasis. Eur J Clin Pharmacol 64:
347–55
Costanzo A, Mazzotta A, Papoutsaki M et al. (2005) Safety and efficacy
study on etanercept in patients with plaque psoriasis. Br J Dermatol
152:187–9
Dogra S, Krishna V, Kanwar AJ (2012) Efficacy and safety of systemic
methotrexate in two fixed doses of 10 mg or 25 mg orally once weekly
in adult patients with severe plaque-type psoriasis: a prospective,
randomized, double-blind, dose-ranging study. Clin Exp Dermatol 37:
729–34
Elder CA, Moore M, Chang CT et al. (1995) Efficacy and pharmacokinetics of
two formulations of cyclosporine A in patients with psoriasis. J Clin
Pharmacol 35:865–75
Finzi AF, Mozzanica N, Pigatto PD et al. (1993) Cyclosporine versus etretinate:
Italian multicentre comparative trial in severe psoriasis. Dermatology
187:8–18
Gollnick H, Altmeyer P, Kaufmann R et al. (2002) Topical calcipotriol plus oral
fumaric acid is more effective and faster acting than oral fumaric acid
monotherapy in the treatment of severe chronic plaque psoriasis vulgaris.
Dermatology 205:46–53
Gottlieb AB, Langley RG, Strober BE et al. (2012) A randomized, double-blind,
placebo-controlled study to evaluate the addition of methotrexate to
etanercept in patients with moderate to severe plaque psoriasis. Br J
Dermatol 167:649–57
Gottlieb AB, Leonardi C, Kerdel F et al. (2011) Efficacy and safety of
briakinumab vs. etanercept and placebo in patients with moderate to
severe chronic plaque psoriasis. Br J Dermatol 165:652–60
Gottlieb AB, Matheson RT, Lowe N et al. (2003) A randomized trial of
etanercept as monotherapy for psoriasis. Arch Dermatol 139:1627–32
Gribetz CH, Blum R, Brady C et al. (2005) An extended 16-week course of
alefacept in the treatment of chronic plaque psoriasis. J Am Acad
Dermatol 53:73–5
Griffiths CEM, Strober BE, Van De Kerkhof P et al. (2010) Comparison of
ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J
Med 362:118–28
Grossman RM, Thivolet J, Claudy A et al. (1994) A novel therapeutic approach
to psoriasis with combination calcipotriol ointment and very low-dose
cyclosporine: results of a multicenter placebo-controlled study. J Am Acad
Dermatol 31:68–74
Heydendael VM, Spuls PI, Opmeer BC et al. (2003) Methotrexate versus
cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J
Med 349:658–65
Hick J, Feldman SR (2007) Eligibility creep: a cause for placebo group
improvement in controlled trials of psoriasis treatments. J Am Acad
Dermatol 57:972–6
Higgins JP, Altman DG, Gotzsche PC et al. (2011) The Cochrane Collabora-
tion’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928
Hroch M, Chladek J, Simkova M et al. (2008) A pilot study of pharmacoki-
netically guided dosing of oral methotrexate in the initial phase of
psoriasis treatment. J Eur Acad Dermatol Venereol 22:19–24
Huang PH, Liao YH, Wei CC et al. (2008) Clinical effectiveness and
safety experience with alefacept in the treatment of patients with
moderate-to-severe chronic plaque psoriasis in Taiwan: results of an
open-label, single-arm, multicentre pilot study. J Eur Acad Dermatol
Venereol 22:923–30
Igarashi A, Kato T, Kato M et al. (2012) Efficacy and safety of ustekinumab
in Japanese patients with moderate-to-severe plaque-type psoriasis:
long-term results from a phase 2/3 clinical trial. J Dermatol 39:
242–52
Katz KA (2005) Psoriasis Area and Severity Index 50 as an endpoint in psoriasis
trials: an unconvincing proposal. J Am Acad Dermatol 53:547–51
Koo J (1998) A randomized, double-blind study comparing the efficacy, safety
and optimal dose of two formulations of cyclosporin, Neoral and
Sandimmun, in patients with severe psoriasis. OLP302 Study Group.
Br J Dermatol 139:88–95
Krueger GG, Feldman SR, Camisa C et al. (2000) Two considerations for
patients with psoriasis and their clinicians: what defines mild, moderate,
and severe psoriasis? What constitutes a clinically significant improve-
ment when treating psoriasis? J Am Acad Dermatol 43:281–5
Krueger GG, Papp KA, Stough DB et al. (2002) A randomized, double-blind,
placebo-controlled phase III study evaluating efficacy and tolerability of 2
courses of alefacept in patients with chronic plaque psoriasis. J Am Acad
Dermatol 47:821–33
Laburte C, Grossman R, Abi-Rached J et al. (1994) Efficacy and safety of oral
cyclosporin A (CyA; Sandimmun) for long-term treatment of chronic
severe plaque psoriasis. Br J Dermatol 130:366–75
Lemme G, Campanati A, Paolinelli M et al. (2007) Diffuse psoriasis plaque
type and infliximab: our experience and review of literature. G Ital
Dermatol Venereol 142:9–14
Leonardi CL, Kimball AB, Papp KA et al. (2008) Efficacy and safety of
ustekinumab, a human interleukin-12/23 monoclonal antibody, in
patients with psoriasis: 76-week results from a randomised, double-blind,
placebo-controlled trial (PHOENIX 1). Lancet 371:1665–74
Leonardi CL, Powers JL, Matheson RT et al. (2003) Etanercept as monotherapy
in patients with psoriasis. N Engl J Med 349:2014–22
Lui H, Gulliver W, Tan J et al. (2012) A randomized controlled study of
combination therapy with alefacept and narrow band UVB phototherapy
(UVB) for moderate to severe psoriasis: efficacy, onset, and duration of
response. J Drugs Dermatol 11:929–37
Mahrle G, Schulze HJ, Farber L et al. (1995) Low-dose short-term cyclosporine
versus etretinate in psoriasis: improvement of skin, nail, and joint
involvement. J Am Acad Dermatol 32:78–88
Meffert H, Brautigam M, Farber L et al. (1997) Low-dose (1.25 mg/kg)
cyclosporin A: treatment of psoriasis and investigation of the influence
on lipid profile. Acta Derm Venereol 77:137–41
Menter A, Feldman SR, Weinstein GD et al. (2007) A randomized comparison
of continuous vs. intermittent infliximab maintenance regimens over
1 year in the treatment of moderate-to-severe plaque psoriasis. J Am
Acad Dermatol 56:e1–15
Menter A, Tyring SK, Gordon K et al. (2008) Adalimumab therapy for moderate
to severe psoriasis: A randomized, controlled phase III trial. J Am Acad
Dermatol 58:106–15
Moher D, Liberati A, Tetzlaff J et al. (2009) Preferred reporting items for
systematic reviews and meta-analyses: the PRISMA statement. PLoS Med
6:e1000097
Mrowietz U, Christophers E, Altmeyer P (1998) Treatment of psoriasis with
fumaric acid esters: results of a prospective multicentre study. German
Multicentre Study. Br J Dermatol 138:456–60
Mrowietz U, Kragballe K, Reich K et al. (2011) Definition of treatment goals for
moderate to severe psoriasis: a European consensus. Arch Dermatol Res
303:1–10
Nast A, Boehncke WH, Mrowietz U et al. (2011) [S3-guidelines for the
treatment of psoriasis vulgaris Update 2011]. J Dtsch Dermatol Ges
9(Suppl 2):S1–104
A Nast et al.
Time Until Onset of Antipsoriatic Drugs
www.jidonline.org 1969
Noda S, Mizuno K, Adachi M (2012) Treatment effect of adalimumab and
infliximab in Japanese psoriasis patients: Results in a single community-
based hospital. J Dermatol 39:265–8
Papp KA, Langley RG, Lebwohl M et al. (2008) Efficacy and safety of
ustekinumab, a human interleukin-12/23 monoclonal antibody, in
patients with psoriasis: 52-week results from a randomised, double-blind,
placebo-controlled trial (PHOENIX 2). Lancet 371:1675–84
Pathirana D, Ormerod AD, Saiag P et al. (2009) European S3-guidelines on the
systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol
23(Suppl 2):1–70
Reich K, Langley RG, Papp KA et al. (2011) A 52-week trial comparing
briakinumab with methotrexate in patients with psoriasis. N Engl J Med
365:1586–96
Reich K, Nestle FO, Papp K et al. (2005) Infliximab induction and maintenance
therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-
blind trial. Lancet 366:1367–74
Reitamo S, Spuls P, Sassolas B et al. (2001) Efficacy of sirolimus (rapamycin)
administered concomitantly with a subtherapeutic dose of cyclosporin in
the treatment of severe psoriasis: a randomized controlled trial. Br J
Dermatol 145:438–45
Revicki D, Willian MK, Saurat JH et al. (2008) Impact of adalimumab treatment
on health-related quality of life and other patient-reported outcomes:
results from a 16-week randomized controlled trial in patients with
moderate to severe plaque psoriasis. Br J Dermatol 158:549–57
Saurat JH, Langley RG, Reich K et al. (2011) Relationship between methotrexate
dosing and clinical response in patients with moderate to severe psoriasis:
subanalysis of the CHAMPION study. Br J Dermatol 165:399–406
Saurat JH, Stingl G, Dubertret L et al. (2008) Efficacy and safety results from the
randomized controlled comparative study of adalimumab vs. methotrex-
ate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol
158:558–66
Schafer I, Hacker J, Rustenbach SJ et al. (2010) Concordance of the Psoriasis
Area and Severity Index (PASI) and patient-reported outcomes in psoriasis
treatment. Eur J Dermatol 20:62–7
Schmitt J, Zhang Z, Wozel G et al. (2008) Efficacy and tolerability of biologic
and nonbiologic systemic treatments for moderate-to-severe psoriasis:
meta-analysis of randomized controlled trials. Br J Dermatol 159:513–26
Scottish Intercollegiate Guidelines Network (SIGN) (2010) Diagnosis and
Management of Psoriasis and Psoriatic Arthritis in Adults vol. 121. SIGN:
Edinburgh, 72
Seston EM, Ashcroft DM, Griffiths CE (2007) Balancing the benefits and risks of
drug treatment: a stated-preference, discrete choice experiment with
patients with psoriasis. Arch Dermatol 143:1175–9
Singh JA, Wells GA, Christensen R et al. (2011) Adverse effects of biologics: a
network meta-analysis and Cochrane overview. Cochrane Database Syst
Rev (2), CD008794.
Smith CH, Anstey AV, Barker JN et al. (2005) British Association of
Dermatologists guidelines for use of biological interventions in psoriasis
2005. Br J Dermatol 153:486–97
Strober BE, Crowley JJ, Yamauchi PS et al. (2011) Efficacy and safety results
from a phase III, randomized controlled trial comparing the safety and
efficacy of briakinumab with etanercept and placebo in patients with
moderate to severe chronic plaque psoriasis. Br J Dermatol 165:661–8
Torii H, Nakagawa H (2010) Infliximab monotherapy in Japanese patients
with moderate-to-severe plaque psoriasis and psoriatic arthritis. A rando-
mized, double-blind, placebo-controlled multicenter trial. J Dermatol Sci
59:40–9
Tsai T-F, Ho J-C, Song M et al. (2011) Efficacy and safety of ustekinumab for
the treatment of moderate-to-severe psoriasis: a phase III, randomized,
placebo-controlled trial in Taiwanese and Korean patients (PEARL).
J Dermatol Sci 63:154–63
Tyring S, Gordon KB, Poulin Y et al. (2007) Long-term safety and efficacy of 50
mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol
143:719–26
van de Kerkhof PC, Cambazard F, Hutchinson PE et al. (1998) The effect of
addition of calcipotriol ointment (50 micrograms/g) to acitretin therapy in
psoriasis. Br J Dermatol 138:84–9
van de Kerkhof PC, Segaert S, Lahfa M et al. (2008) Once weekly adminis-
tration of etanercept 50 mg is efficacious and well tolerated in patients
with moderate-to-severe plaque psoriasis: a randomized controlled trial
with open-label extension. Br J Dermatol 159:1177–85
Vena GA, Galluccio A, Pezza M et al. (2012) Combined treatment with low-
dose cyclosporine and calcipotriol/betamethasone dipropionate ointment
for moderate-to-severe plaque psoriasis: a randomized controlled open-
label study. J Dermatolog Treat 23:255–60
Yang H-Z, Wang K, Jin H-Z et al. (2012) Infliximab monotherapy for Chinese
patients with moderate to severe plaque psoriasis: a randomized, double-
blind, placebo-controlled multicenter trial. Chin Med J 125:1845–51
Yoon HS, Youn JI (2007) A comparison of two cyclosporine dosage regimens
for the treatment of severe psoriasis. J Dermatolog Treat 18:286–90
A Nast et al.
Time Until Onset of Antipsoriatic Drugs
1970 Journal of Investigative Dermatology (2013), Volume 133
